Skip to main content
main-content

11.10.2015 | Original Article | Ausgabe 3/2016

Tumor Biology 3/2016

Plasma miR-940 may serve as a novel biomarker for gastric cancer

Zeitschrift:
Tumor Biology > Ausgabe 3/2016
Autoren:
Xin Liu, Ava Kwong, Alan Sihoe, Kent-Man Chu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s13277-015-4019-5) contains supplementary material, which is available to authorized users.

Abstract

It was reported that circulating microRNAs could be applied as non-invasive biomarkers for cancer monitoring. The purpose of this study was to identify plasma miRNA that may serve as a novel biomarker for gastric cancer and to evaluate its clinical application. MicroRNA profiles were generated from plasma samples of 5 patients with gastric cancer (GC) versus 5 healthy controls (HC). MicroRNA-940 (miR-940) was one of the most downregulated miRNAs with fold change of 0.164. It was revealed that the expression of miR-940 was downregulated in both the initial set (N = 30, P < 0.0001) and the validation set (N = 80, P < 0.0001) of plasma samples of patients with gastric cancer. The sensitivity was obviously higher than the current biomarkers CEA and CA19-9 (81.25 % vs. 22.54 % and 15.71 %). MiR-940 was also significantly downregulated in gastric cancer tissue samples (N = 34, P = 0.0015), as well as in cancer cell lines (N = 7). Importantly, miR-940 was significantly highly expressed in stomach tissue samples than in other types of tissue samples including the liver, breast, thyroid, and lung. Moreover, there was a trend of lower expression of miR-940 from early to advanced stage of gastric cancer. Target prediction suggested that miR-940 regulated cell signaling including NF-κB and Wnt/β-catenin, as well as pathways of cell communication and adhesion. These pathways play critical roles in gastric cancer initiation and progression. It is the first report that miR-940 may mainly express in the stomach. Downregulation of plasma miR-940 may serve as a novel biomarker for detection of gastric cancer.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
High-resolution image (TIFF 195 kb)
13277_2015_4019_MOESM1_ESM.tif
High-resolution image (TIFF 76.5 kb)
13277_2015_4019_MOESM2_ESM.tif
High-resolution image (TIFF 74.3 kb)
13277_2015_4019_MOESM3_ESM.tif
High-resolution image (TIFF 81.7 kb)
13277_2015_4019_MOESM4_ESM.tif
High-resolution image (TIFF 99.1 kb)
13277_2015_4019_MOESM5_ESM.tif
Supplementary Table 1 (PDF 59.5 kb)
13277_2015_4019_MOESM6_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2016

Tumor Biology 3/2016 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise